CytoDyn Announces Investor Call to Provide Update on Clinical Development Strategy

... (U.S./Canada) or 201-612-7415 (International); Conference ID: 13578723. PRO 140 belongs to a new class of HIV/AIDS therapeutics -- viral-entry inhibitors -- that are intended to protect healthy cells from viral infection. PRO 140 is a humanized ...

http://ift.tt/1j2XmWE